K Kantarci

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi Proton MRS in mild cognitive impairment
    Kejal Kantarci
    Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA
    J Magn Reson Imaging 37:spcone. 2013
  2. ncbi Proton MRS in mild cognitive impairment
    Kejal Kantarci
    Department of Radiology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Magn Reson Imaging 37:770-7. 2013
  3. ncbi Multimodality imaging characteristics of dementia with Lewy bodies
    Kejal Kantarci
    Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA
    Neurobiol Aging 33:2091-105. 2012
  4. ncbi Focal atrophy on MRI and neuropathologic classification of dementia with Lewy bodies
    Kejal Kantarci
    Departments of Radiology, Mayo Clinic, Rochester, MN, USA
    Neurology 79:553-60. 2012
  5. ncbi Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies
    Jonathan Graff-Radford
    Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Brain 135:2470-7. 2012
  6. ncbi Antemortem amyloid imaging and β-amyloid pathology in a case with dementia with Lewy bodies
    Kejal Kantarci
    Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA
    Neurobiol Aging 33:878-85. 2012
  7. ncbi 1H magnetic resonance spectroscopy in dementia
    K Kantarci
    Department of Radiology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Br J Radiol 80:S146-52. 2007
  8. ncbi Alzheimer disease: postmortem neuropathologic correlates of antemortem 1H MR spectroscopy metabolite measurements
    Kejal Kantarci
    Departments of Radiology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Radiology 248:210-20. 2008
  9. ncbi Risk of dementia in MCI: combined effect of cerebrovascular disease, volumetric MRI, and 1H MRS
    K Kantarci
    Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Neurology 72:1519-25. 2009
  10. ncbi Effects of age on the glucose metabolic changes in mild cognitive impairment
    Kejal Kantarci
    Department of Radiology, Mayo Clinic, Rochester, Minnesota 55905, USA
    AJNR Am J Neuroradiol 31:1247-53. 2010

Research Grants

  1. 1H MRS markers of MCI syndromes and common dementias
    Kejal Kantarci; Fiscal Year: 2007

Detail Information

Publications43

  1. ncbi Proton MRS in mild cognitive impairment
    Kejal Kantarci
    Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA
    J Magn Reson Imaging 37:spcone. 2013
    ..J. Magn. Reson. Imaging 2013;37:770-777. © 2012 Wiley Periodicals, Inc...
  2. ncbi Proton MRS in mild cognitive impairment
    Kejal Kantarci
    Department of Radiology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Magn Reson Imaging 37:770-7. 2013
    ..The role of proton MRS will be critical for pathophysiological processes for which a reliable biomarker does not exist such as neuronal dysfunction, glial and microglial activation in MCI...
  3. ncbi Multimodality imaging characteristics of dementia with Lewy bodies
    Kejal Kantarci
    Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA
    Neurobiol Aging 33:2091-105. 2012
    ..Occipital and posterior parietotemporal lobe hypometabolism is a distinguishing feature of DLB and this regional hypometabolic pattern is independent of the amyloid pathology...
  4. ncbi Focal atrophy on MRI and neuropathologic classification of dementia with Lewy bodies
    Kejal Kantarci
    Departments of Radiology, Mayo Clinic, Rochester, MN, USA
    Neurology 79:553-60. 2012
    ..To determine the association between the focal atrophy measures on antemortem MRI and postmortem neuropathologic classification of dementia with Lewy bodies (DLB) using the Third Report of the DLB Consortium criteria...
  5. ncbi Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies
    Jonathan Graff-Radford
    Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Brain 135:2470-7. 2012
    ..Patients with dementia with Lewy bodies who do not have the imaging features of coexistent Alzheimer's disease-related pathology are more likely to cognitively improve with acetylcholinesterase inhibitor treatment...
  6. ncbi Antemortem amyloid imaging and β-amyloid pathology in a case with dementia with Lewy bodies
    Kejal Kantarci
    Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA
    Neurobiol Aging 33:878-85. 2012
    ..36; p = 0.17). The ROI-based analysis of imaging and histopathological data confirms that PiB uptake on PET is a specific marker for Aβ density, but cannot differentiate neuritic from diffuse amyloid plaques in this case with DLB...
  7. ncbi 1H magnetic resonance spectroscopy in dementia
    K Kantarci
    Department of Radiology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Br J Radiol 80:S146-52. 2007
    ..Overall, MRS is a promising investigational technique in ageing and dementia at this time. The potential clinical application of MRS in ageing and dementia, however, is growing with technical advances in the field...
  8. ncbi Alzheimer disease: postmortem neuropathologic correlates of antemortem 1H MR spectroscopy metabolite measurements
    Kejal Kantarci
    Departments of Radiology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Radiology 248:210-20. 2008
    ..To determine the neuropathologic correlates of antemortem hydrogen 1 ((1)H) magnetic resonance (MR) spectroscopy metabolite measurements in subjects with Alzheimer disease (AD)-type pathology...
  9. ncbi Risk of dementia in MCI: combined effect of cerebrovascular disease, volumetric MRI, and 1H MRS
    K Kantarci
    Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Neurology 72:1519-25. 2009
    ..To investigate the combined ability of hippocampal volumes, 1H magnetic resonance spectroscopy (MRS) metabolites, and cerebrovascular disease to predict the risk of progression to dementia in mild cognitive impairment (MCI)...
  10. ncbi Effects of age on the glucose metabolic changes in mild cognitive impairment
    Kejal Kantarci
    Department of Radiology, Mayo Clinic, Rochester, Minnesota 55905, USA
    AJNR Am J Neuroradiol 31:1247-53. 2010
    ..Decreased glucose metabolism in the temporal and parietal lobes on FDG-PET is recognized as an early imaging marker for the AD pathology. Our objective was to investigate the effects of age on FDG-PET findings in aMCI...
  11. ncbi Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's disease
    Kejal Kantarci
    Department of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Neurobiol Aging 28:1330-9. 2007
    ..Choline/creatine ratio declined in stable MCI, compared to converter MCI patients and cognitively normal elderly, which may be related to a compensatory mechanism in MCI patients who did not to progress to AD...
  12. ncbi Dementia with Lewy bodies and Alzheimer disease: neurodegenerative patterns characterized by DTI
    K Kantarci
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Neurology 74:1814-21. 2010
    ....
  13. ncbi Diffusion tensor imaging and cognitive function in older adults with no dementia
    K Kantarci
    Department of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Neurology 77:26-34. 2011
    ..To determine the patterns of diffusivity associated with cognitive domain functions in older adults without dementia...
  14. ncbi Magnetic resonance markers for early diagnosis and progression of Alzheimer's disease
    Kejal Kantarci
    Department of Radiology, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA
    Expert Rev Neurother 5:663-70. 2005
    ..In order for magnetic resonance modalities to qualify as surrogate markers for early diagnosis and progression of Alzheimer's disease, multicenter longitudinal studies are needed...
  15. ncbi Magnetic resonance spectroscopy, β-amyloid load, and cognition in a population-based sample of cognitively normal older adults
    Kejal Kantarci
    Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 77:951-8. 2011
    ....
  16. ncbi Neuroimaging in Alzheimer disease: an evidence-based review
    Kejal Kantarci
    Department of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Neuroimaging Clin N Am 13:197-209. 2003
    ....
  17. ncbi Hippocampal volumes, proton magnetic resonance spectroscopy metabolites, and cerebrovascular disease in mild cognitive impairment subtypes
    Kejal Kantarci
    Department of Diagnostic Radiology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Arch Neurol 65:1621-8. 2008
    ..Noninvasive imaging surrogates for underlying pathological findings in MCI would be clinically useful for identifying patients who may benefit from disease-specific treatments at the prodromal stage of dementia...
  18. ncbi APOE modifies the association between Aβ load and cognition in cognitively normal older adults
    K Kantarci
    Department of Radiology, Mayo Clinic, Rochester, MN, USA
    Neurology 78:232-40. 2012
    ..To determine the relationship between β-amyloid (Aβ) load as measured by [(11)C]-Pittsburgh compound B (PiB) PET and cognitive function in cognitively normal older adults...
  19. ncbi DWI predicts future progression to Alzheimer disease in amnestic mild cognitive impairment
    K Kantarci
    Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 64:902-4. 2005
    ..002). Magnetic resonance diffusion-weighted imaging may help identify patients with aMCI who will progress to AD as well as or better than structural MRI measures of hippocampal atrophy...
  20. ncbi Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease
    D S Knopman
    Department of Neurology, Mayo Clinic Alzheimer s Disease Research Center, Rochester, MN, USA
    Neurology 78:1576-82. 2012
    ..Stage 0, not explicitly defined in the criteria, represents subjects with normal biomarkers and normal cognition. The ability of the recommended criteria to predict progression to cognitive impairment is the crux of their validity...
  21. ncbi Gray and white matter water diffusion in the syndromic variants of frontotemporal dementia
    J L Whitwell
    Department of Radiology, Mayo Clinic, Rochester MN 55905, USA
    Neurology 74:1279-87. 2010
    ..To use diffusion tensor imaging (DTI) to assess gray matter and white matter tract diffusion in behavioral variant frontotemporal dementia (bvFTD), semantic dementia (SMD), and progressive nonfluent aphasia (PNFA)...
  22. ncbi 1H MR spectroscopy in common dementias
    K Kantarci
    Department of Diagnostic Radiology, Mayo Clinic 200 First St. SW, Rochester, MN 55905, USA
    Neurology 63:1393-8. 2004
    ..MI/Cr levels are elevated in dementias that are pathologically characterized by gliosis, such as AD and FTLD. Cho/Cr levels are elevated in dementias that are characterized by a profound cholinergic deficit, such as AD and DLB...
  23. ncbi MRS in presymptomatic MAPT mutation carriers: a potential biomarker for tau-mediated pathology
    K Kantarci
    Departmentsof Radiology, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 75:771-8. 2010
    ..To determine the proton magnetic resonance spectroscopy ((1)H MRS) changes in carriers of microtubule-associated protein (MAPT) mutations in a case-control study...
  24. ncbi Mild cognitive impairment and Alzheimer disease: regional diffusivity of water
    K Kantarci
    Department of Diagnostic Radiology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Radiology 219:101-7. 2001
    ..Elevation in hippocampal ADC may reflect early ultrastructural changes in the progression of Alzheimer disease...
  25. ncbi MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study
    J L Whitwell
    Department of Radiology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Neurology 71:743-9. 2008
    ..We aimed to determine whether patterns of gray matter atrophy from antemortem MRI correlate with Braak staging of NFT pathology...
  26. ncbi Neuroimaging comparison of primary progressive apraxia of speech and progressive supranuclear palsy
    J L Whitwell
    Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA
    Eur J Neurol 20:629-37. 2013
    ..We aimed to compare, for the first time, atrophy patterns, as well as white matter tract degeneration, between these two syndromes...
  27. ncbi Patterns of atrophy differ among specific subtypes of mild cognitive impairment
    Jennifer L Whitwell
    Department of Radiology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Arch Neurol 64:1130-8. 2007
    ..It follows, however, that subjects with MCI who have impairment in nonmemory domains may progress to non-AD degenerative dementias...
  28. ncbi 1H magnetic resonance spectroscopy, cognitive function, and apolipoprotein E genotype in normal aging, mild cognitive impairment and Alzheimer's disease
    Kejal Kantarci
    Department of Diagnostic Radiology, Mayo Clinic, Rochester, Minnesota 55901, USA
    J Int Neuropsychol Soc 8:934-42. 2002
    ..Among 1H-MRS measurements, the NAA/MI ratio maybe the most efficient predictor of memory and cognitive function in patients with MCI and AD...
  29. ncbi Comparative diagnostic utility of different MR modalities in mild cognitive impairment and Alzheimer's disease
    Kejal Kantarci
    Department of Diagnostic Radiology, Mayo Clinic, Rochester, Minn, USA
    Dement Geriatr Cogn Disord 14:198-207. 2002
    ..Selection of imaging measures used for clinical assessment or monitoring efficiency of therapeutic intervention should be tailored to the clinical stage of the disease...
  30. ncbi Proton MR spectroscopy in mild cognitive impairment and Alzheimer disease: comparison of 1.5 and 3 T
    Kejal Kantarci
    Department of Diagnostic Radiology, Milwaukee, WI, USA
    AJNR Am J Neuroradiol 24:843-9. 2003
    ..05). CONCLUSION: With currently available technology, the diagnostic performance of (1)H MR spectroscopy in patients with MCI and those with AD was not better at 3 T than at 1.5 T...
  31. ncbi Similar clinical and neuroimaging features in monozygotic twin pair with mutation in progranulin
    E McDade
    Department of Neurology, Mayo Clinic, Rochester, MN, USA
    Neurology 78:1245-9. 2012
    ..To report the phenotypic characterization of monozygotic twins with mutations encoding progranulin (PGRN)...
  32. ncbi Inclusion of RBD improves the diagnostic classification of dementia with Lewy bodies
    T J Ferman
    Department of Psychiatry and Psychology, Mayo Clinic, Jacksonville, FL 32224, USA
    Neurology 77:875-82. 2011
    ..To determine whether adding REM sleep behavior disorder (RBD) to the dementia with Lewy bodies (DLB) diagnostic criteria improves classification accuracy of autopsy-confirmed DLB...
  33. ncbi Quantitative magnetic resonance techniques as surrogate markers of Alzheimer's disease
    Kejal Kantarci
    Department of Radiology, Mayo Clinic, Rochester, Minnesota 55905, USA
    NeuroRx 1:196-205. 2004
    ..As with indirect MR measures, these approaches of directly imaging the pathological substrate will need to undergo a validation process with longitudinal studies to prove their usefulness as surrogate markers in AD...
  34. ncbi Untreated type 2 diabetes and its complications are associated with subcortical infarctions
    Rosebud O Roberts
    Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA
    Diabetes Care 34:184-6. 2011
    ..To investigate the association of type 2 diabetes with subcortical infarctions...
  35. ncbi Imaging correlates of posterior cortical atrophy
    Jennifer L Whitwell
    Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA
    Neurobiol Aging 28:1051-61. 2007
    ..1)H MRS suggested loss of neuronal integrity and glial activation in subjects with PCA and typical AD. The differing patterns of atrophy on MRI suggest that PCA should be considered a distinct entity from typical AD...
  36. ncbi Frontotemporal dementia and parkinsonism associated with the IVS1+1G->A mutation in progranulin: a clinicopathologic study
    Bradley F Boeve
    Department of Neurology, Mayo Clinic Rochester, MN 55905, USA
    Brain 129:3103-14. 2006
    ..These findings suggest that the insR352 PSEN1 is not pathogenic, and the IVS1+1G-->A mutation in PGRN causes FTDP associated with FTLD-U pathology and represents a new class of neurodegenerative disease--the 'hypoprogranulinopathies'...
  37. ncbi Antemortem differential diagnosis of dementia pathology using structural MRI: Differential-STAND
    Prashanthi Vemuri
    Department of Radiology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Neuroimage 55:522-31. 2011
    ....
  38. ncbi Comparative diagnostic utility of 1H MRS and DWI in evaluation of temporal lobe epilepsy
    K Kantarci
    Department of Diagnostic Radiology, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 58:1745-53. 2002
    ..05). CONCLUSION: (1)H MRS and DWI complement each other in the clinical setting. DWI more frequently lateralized to the operated side, and (1)HMRS was a better predictor of postoperative seizure control...
  39. ncbi Mild cognitive impairment associated with limbic and neocortical Lewy body disease: a clinicopathological study
    Jennifer Molano
    Mayo Clinic, Rochester, MN 55905, USA
    Brain 133:540-56. 2010
    ....
  40. ncbi Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage
    Prashanthi Vemuri
    Department of Radiology, Mayo Clinic Rochester, Rochester, MN 55905, USA
    Neuroimage 42:559-67. 2008
    ....
  41. ncbi Alzheimer's disease diagnosis in individual subjects using structural MR images: validation studies
    Prashanthi Vemuri
    Department of Radiology, Mayo Clinic 200 1st St SW, Rochester, MN 55905, USA
    Neuroimage 39:1186-97. 2008
    ..To develop and validate a tool for Alzheimer's disease (AD) diagnosis in individual subjects using support vector machine (SVM)-based classification of structural MR (sMR) images...
  42. ncbi The role of biomarkers in clinical trials for Alzheimer disease
    Leon J Thal
    University of California San Diego, Department of Neurosciences, La Jolla, California, USA
    Alzheimer Dis Assoc Disord 20:6-15. 2006
    ..Additionally, biochemical biomarkers in blood or cerebrospinal fluid are assessed. Currently appropriate uses of biomarkers in the study of Alzheimer disease, and areas where additional work is needed, are discussed...
  43. ncbi Lateralized and focal clinical, EEG, and FLAIR MRI abnormalities in Creutzfeldt-Jakob disease
    Denise M Cambier
    Department of Neurology, Ohio State University, Columbus, OH, USA
    Clin Neurophysiol 114:1724-8. 2003
    ..SIGNIFICANCE: CJD can sometimes present with more focal or lateralized clinical findings, and the colocalizing EEG and MRI findings can help make or confirm the diagnosis of CJD...

Research Grants2

  1. 1H MRS markers of MCI syndromes and common dementias
    Kejal Kantarci; Fiscal Year: 2007
    ....